Modern medicamentous treatment of epilepsy in adults
Abstract
Background: Several »newer« antiepileptic drugs (AEDs), i.e. vigabatrin, lamotrigine, gabapentin, topiramate, tiagabine, oxcarbazepine, levetiracetam, pregabalin and zonisamide have been introduced into clinical practice within the last decade. Most of these new drugs are at least as effective as the »older« AEDs (phenobarbital, phenytoin, valproic acid, carbamazepine) and in general, they seem to be better tolerated then the older drugs and have less side effects. The development of pharmaceutical industry has brought several new AEDs to clinical practice which increased a probability of therapeutic success, but also made treatment more complex. It is expected from the physician that she will know indications and contraindications for at least 15 AEDs, their optimal titration, dosage, possible side effects and wide spectrum of interactions with other drugs. At this point advertisements of drug companies try to convince us aggressively about success of their own products.
Conclusions: This review article focuses on modern medicamentous treatment of adults with epilepsy, main characteristics of newer AEDs, conditions, availability and statistics of their usage in Slovenia.
Downloads
References
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314–9.
Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531–43.
Stefan H, Halasz P, Gil-Nagel A, Shorvon S, Bauer G, Ben-Menachem E, et al. Recent advances in the diagnosis and treatment of epilepsy. Eur J Neurol 2001; 8: 519–39.
Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A doubleblind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70–6.
Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476–9.
Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23: 149–55.
Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin vs. carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995; 52: 989–96.
Tanganelli P, Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res 1996; 25: 257–62.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252–60.
Schachter SC, Vazquez B, Fisher RS, Laxer KD, Montouris GD, Combs-Cantrell DT, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999, Mar 10; 52(4): 732–7.
Brodie MJ, Chadwick DW, Anhut H, Otte A, Messmer SL, Maton S, et al. Gabapentin Study Group 945-212. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002; 43: 993–1000.
Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169–74.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261–73.
Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs 2002; 62: 593–604.
Meador KJ, Loring DW, Ray PG, Murro AM, King DW, Perrine KR, et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 2001; 56: 1177–82.
Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005; 5: 3–14.
Perucca E, Dulac O, Shorvon S, Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs 2001; 15: 609–21.
Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41: 1364–74.
Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6: 108–13.
Brodie MJ, Schachter SC, Kwan P. Fast facts – Epilepsy. Oxford: Health Press Limited; 2005.
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246–55.
Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255–60.
Mohanraj R, Brodie MJ. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav 2005; 6: 382–7.
Schapel G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure 1996; 5: 153-6.
Jackson MJ. Choice of antiepileptic drug, which one to try first and what to do if it fails. Practical Neurology 2005; 5: 6–17.
Deckers CL, Genton P, Sills GJ, Schmidt D. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res 2003; 53: 1–17.
Stefan H, Lopes da Silva FH, Loscher W, Schmidt D, Perucca E, Brodie MJ, et al. Epileptogenesis and rational therapeutic strategies. Acta Neurol Scand 2006; 113: 139–55.
Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand Suppl 2005; 181: 30–5.
Shorvon SD. Handbook of epilepsy treatment. Oxford: Blackwell Science Ltd.; 2000.
Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193–8.
Albani F, Grassi B, Ferrara R, Turrini R, Baruzzi A. Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch. Seizure 2004; 13: 254–63.
Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81–7.
P-Codrea Tigaran S, Sidenius P, Dam M. Lamotrigine-induced rash-worth a rechallenge. Acta Neurol Scand 2005; 111: 191–4.
Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002; 63: 1012–9.
Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure 2000; 9: 282–6.
Tennis P, Eldridge RR. International Lamotrigine Pregnancy Registry Scientific Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002; 43: 1161–7.
Meador KJ, Loring DW, Vahle VJ, Ray PG, Werz MA, Fessler AJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64: 2108–14.
Lamb EJ, Stevens PE, Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 2004; 41: 166–9.
Opp J, Tuxhorn I, May T, Kluger G, Wiemer-Kruel A, Kurlemann G, et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005; 14: 476– 84.
Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003; 12: 131–5.
Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience. Seizure 2004; 13 Suppl 1: 41–8.Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988; 38: 928– 31.
Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainen E, Partanen J, Partanen K, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922–6.
Williams J, Bialer M, Johannessen SI, Kramer G, Levy R, Mattson RH, et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia 2003; 44: 40–5.
Encouraging Future for Lacosamide in Epilepsy (editorial). Pharmaceutical & Diagnostic Innovation 2005; Vol. 3, No.1.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
